Replies to post #250911 on Biotech Values

[TheFinalCD]

wow $AKRO the robots gapped and trapped people up to $58.20 now almost half that $30.50

wonder if this bounces or even holds $30?

any opinions are welcomed

Message in reply to:
Based on today's dataset, AKRO is seeking to resuscitate the failed phase-2 trial in cirrhotic NASH:

https://www.fiercebiotech.com/biotech/akero-bruised-earlier-failure-soars-liver-scarring-improves-longer-mash-trial

[DewDiligence]

AKRO starts phase-3 trial in cirrhotic MASH:

https://www.globenewswire.com/news-release/2024/06/11/2896641/0/en/Akero-Therapeutics-Announces-Initiation-of-Phase-3-SYNCHRONY-Outcomes-Trial-of-Efruxifermin-in-Patients-with-Compensated-Cirrhosis-F4-Due-to-MASH.html

“Based on the encouraging week 36 results of our Phase 2b SYMMETRY study in patients with compensated cirrhosis due to MASH, we believe EFX has the potential to be among the first investigational drugs to be approved for treatment of both pre-cirrhotic and cirrhotic patients.”

The primary outcomes endpoint is all-cause mortality and liver-related clinical outcomes as measured by time to first occurrence of any of the pre-defined, adjudicated events across both study cohorts...